M. Leinonen

Efficacy and safety of entacapone in Parkinson's disease patients with suboptimal Levodopa response: a 6-month randomized placebo-controlled double-blind study in Germany and Austria (Celomen study)

Werner Poewe, Günther Deuschl, A. Gordin et al. · Acta Neurologica Scandinavica · 2002 · 208 citations

Twelve‐month safety of entacapone in patients with Parkinson’s disease

Vilho V. Myllylä, E.‐R. Kultalahti, Helena Haapaniemi et al. · European Journal of Neurology · 2001 · 84 citations

Psychoactive Drug, Entacapone Patients, Pharmacology +10

The tolerability and efficacy of entacapone over 3 years in patients with Parkinson's disease

Jan Larsen, J Worm-Petersen, Å Sidén et al. · European Journal of Neurology · 2003 · 80 citations

Twelve versus 36 months of adjuvant imatinib (IM) as treatment of operable GIST with a high risk of recurrence: Final results of a randomized trial (SSGXVIII/AIO).

Heikki Joensuu, Mikael Eriksson, J. Hatrmann et al. · Journal of Clinical Oncology · 2011 · 79 citations

Surgical Oncology, Cancer Management, Immunology +16

Pre-Eclampsia Is a Risk Factor of Carotid Artery Atherosclerosis

L. Haukkamaa, Leena Moilanen, Anna Kattainen et al. · Cerebrovascular Diseases · 2009 · 48 citations